Random Trial for Elderly Patients With NSCLC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00265694|
Recruitment Status : Unknown
Verified June 2005 by Inje University.
Recruitment status was: Recruiting
First Posted : December 15, 2005
Last Update Posted : December 15, 2005
- Recently a radomized trial of vinorelbine versus best supportive care in patients at 70 years of age or older demonstrated a definite improvement in overall survival rate and quality of life with chemotherapy.
- The role of combination therapy containing the platinum compound, which is the standard therapy for the young patients is still vague.
- Gemcitabine and carboplatin have favorable toxicity profile.
|Condition or disease||Intervention/treatment||Phase|
|Non-Small Cell Lung Cancer||Drug: vinorelbine, gemcitabine and carboplatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Phase III Trial of Vinorelbine Versus Gemcitabine and Carboplatin for Elderly Patients With Advanced Non-Small Cell Lung Cancer|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00265694
|Contact: Young Jin Yuh, M.D.||email@example.com|
|Korea, Republic of|
|Inje University Sanggyepaik Hospital||Recruiting|
|Seoul, Korea, Republic of, 139-707|
|Contact: Young Jin Yuh, M.D. 82-2-950-1460 firstname.lastname@example.org|
|Principal Investigator: Young Jin Yuh, M.D.|
|Principal Investigator:||Young Jin Yuh, M.D.|